CTLA4 blockade reduces immature myeloid cells in head and neck squamous cell carcinoma

References

• Hashibe M, Brennan P, Chuang SC, Boccia S, Castellsague X, Chen C, Curado MP, Dal Maso L, Daudt AW, Fabianova E et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev 2009; 18:541-50; PMID:19190158; http://dx.doi.org/10.1158/1055-9965.EPI-08-0347
   PubMed Web of Science ®Google Scholar
• Tong CC, Kao J, Sikora AG. Recognizing and reversing the immunosuppressive tumor microenvironment of head and neck cancer. Immunol Res 2012; 54:266-74; PMID:22454102; http://dx.doi.org/10.1007/s12026-012-8306-6
   PubMed Web of Science ®Google Scholar
• Quan J, Johnson NW, Zhou G, Parsons PG, Boyle GM, Gao J. Potential molecular targets for inhibiting bone invasion by oral squamous cell carcinoma: a review of mechanisms. Cancer Metastasis Rev 2012; 31:209-19; PMID:22101806; http://dx.doi.org/10.1007/s10555-011-9335-7
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015; 27:450-61; PMID:25858804; http://dx.doi.org/10.1016/j.ccell.2015.03.001
   PubMed Web of Science ®Google Scholar
• Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995; 3:541-7; PMID:7584144; http://dx.doi.org/10.1016/1074-7613(95)90125-6
   PubMed Web of Science ®Google Scholar
• Lenschow DJ, Herold KC, Rhee L, Patel B, Koons A, Qin HY, Fuchs E, Singh B, Thompson CB, Bluestone JA. CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity 1996; 5:285-93; PMID:8808683; http://dx.doi.org/10.1016/S1074-7613(00)80323-4
   PubMed Web of Science ®Google Scholar
• Hathcock KS, Laszlo G, Pucillo C, Linsley P, Hodes RJ. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J Exp Med 1994; 180:631-40; PMID:7519245; http://dx.doi.org/10.1084/jem.180.2.631
   PubMed Web of Science ®Google Scholar
• Peggs KS, Quezada SA. Ipilimumab: attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma. Expert Rev Anticancer Ther 2010; 10:1697-701; PMID:21080797; http://dx.doi.org/10.1586/era.10.144
   PubMed Web of Science ®Google Scholar
• Galdiero MR, Bonavita E, Barajon I, Garlanda C, Mantovani A, Jaillon S. Tumor associated macrophages and neutrophils in cancer. Immunobiology 2013; 218:1402-10; PMID:23891329; http://dx.doi.org/10.1016/j.imbio.2013.06.003
   PubMed Web of Science ®Google Scholar
• Ochando JC, Chen SH. Myeloid-derived suppressor cells in transplantation and cancer. Immunol Res 2012; 54:275-85; PMID:22535241; http://dx.doi.org/10.1007/s12026-012-8335-1
   PubMed Web of Science ®Google Scholar
• Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 2006; 16:53-65; PMID:16168663; http://dx.doi.org/10.1016/j.semcancer.2005.07.005
   PubMed Web of Science ®Google Scholar
• Weed DT, Vella JL, Reis IM, De la Fuente AC, Gomez C, Sargi Z, Nazarian R, Califano J, Borrello I, Serafini P. Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res 2015; 21:39-48; PMID:25320361; http://dx.doi.org/10.1158/1078-0432.CCR-14-1711
   PubMed Web of Science ®Google Scholar
• Liu Y, Cao X. The origin and function of tumor-associated macrophages. Cell Mol Immunol 2015; 12:1-4; http://dx.doi.org/10.1038/cmi.2014.83
   PubMed Web of Science ®Google Scholar
• Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, Rimoldi M, Biswas SK, Allavena P, Mantovani A. Macrophage polarization in tumour progression. Semin Cancer Biol 2008; 18:349-55; PMID:18467122; http://dx.doi.org/10.1016/j.semcancer.2008.03.004
   PubMed Web of Science ®Google Scholar
• Ostuni R, Kratochvill F, Murray PJ, Natoli G. Macrophages and cancer: from mechanisms to therapeutic implications. Trends Immunol 2015; 36:229-39; PMID:25770924; http://dx.doi.org/10.1016/j.it.2015.02.004
   PubMed Web of Science ®Google Scholar
• Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 2007; 9:166-80; PMID:17356713; http://dx.doi.org/10.1593/neo.07112
   PubMed Web of Science ®Google Scholar
• Trellakis S, Bruderek K, Hutte J, Elian M, Hoffmann TK, Lang S, Brandau S. Granulocytic myeloid-derived suppressor cells are cryosensitive and their frequency does not correlate with serum concentrations of colony-stimulating factors in head and neck cancer. Innate Immun 2013; 19:328-36; PMID:23160385; http://dx.doi.org/10.1177/1753425912463618
   PubMed Web of Science ®Google Scholar
• Lyford-Pike S, Peng S, Young GD, Taube JM, Westra WH, Akpeng B, Bruno TC, Richmon JD, Wang H, Bishop JA et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res 2013; 73:1733-41; PMID:23288508; http://dx.doi.org/10.1158/0008-5472.CAN-12-2384
   PubMed Web of Science ®Google Scholar
• Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M, Cozen W et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011; 29:4294-301; PMID:21969503; http://dx.doi.org/10.1200/JCO.2011.36.4596
   PubMed Web of Science ®Google Scholar
• Sepiashvili L, Bruce JP, Huang SH, O'Sullivan B, Liu FF, Kislinger T. Novel insights into head and neck cancer using next-generation “omic” technologies. Cancer Res 2015; 75:480-6; PMID:25589349; http://dx.doi.org/10.1158/0008-5472.CAN-14-3124
   PubMed Web of Science ®Google Scholar
• Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer 2011; 11:9-22; PMID:21160525; http://dx.doi.org/10.1038/nrc2982
   PubMed Web of Science ®Google Scholar
• Bian Y, Hall B, Sun ZJ, Molinolo A, Chen W, Gutkind JS, Waes CV, Kulkarni AB. Loss of TGF-β signaling and PTEN promotes head and neck squamous cell carcinoma through cellular senescence evasion and cancer-related inflammation. Oncogene 2012; 31:3322-32; PMID:22037217; http://dx.doi.org/10.1038/onc.2011.494
   PubMed Web of Science ®Google Scholar
• Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev 2009; 229:12-26; PMID:19426212; http://dx.doi.org/10.1111/j.1600-065X.2009.00770.x
   PubMed Web of Science ®Google Scholar
• Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565-70; PMID:21436444; http://dx.doi.org/10.1126/science.1203486
   PubMed Web of Science ®Google Scholar
• Czystowska M, Gooding W, Szczepanski MJ, Lopez-Abaitero A, Ferris RL, Johnson JT, Whiteside TL. The immune signature of CD8(+)CCR7(+) T cells in the peripheral circulation associates with disease recurrence in patients with HNSCC. Clin Cancer Res 2013; 19:889-99; PMID:23363813; http://dx.doi.org/10.1158/1078-0432.CCR-12-2191
   PubMed Web of Science ®Google Scholar
• Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1:405-13; PMID:7882171; http://dx.doi.org/10.1016/1074-7613(94)90071-X
   PubMed Web of Science ®Google Scholar
• He KF, Zhang L, Huang CF, Ma SR, Wang YF, Wang WM, Zhao ZL, Liu B, Zhao YF, Zhang WF et al. CD163+ tumor-associated macrophages correlated with poor prognosis and cancer stem cells in oral squamous cell carcinoma. Biomed Res Int 2014; 2014:838632; PMID:24883329; http://dx.doi.org/10.1155/2014/838632.
   PubMed Web of Science ®Google Scholar
• Martin D, Abba MC, Molinolo AA, Vitale-Cross L, Wang Z, Zaida M, Delic NC, Samuels Y, Lyons JG, Gutkind JS. The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies. Oncotarget 2014; 5:8906-23; PMID:25275298; http://dx.doi.org/10.18632/oncotarget.2417
   PubMed Web of Science ®Google Scholar
• Partlova S, Boucek J, Kloudova K, Lukesova E, Zabrodsky M, Grega M, Fucikova J, Truxova I, Tachezy R, Spisek R et al. Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma. Oncoimmunology 2015; 4:e965570; PMID:25949860; http://dx.doi.org/10.4161/21624011.2014.965570
   PubMed Web of Science ®Google Scholar
• Flemming A. Cancer: Re-educating tumour-associated macrophages. Nat Rev Drug Discov 2011; 10:177; PMID:21358735; http://dx.doi.org/10.1038/nrd3399
   PubMed Web of Science ®Google Scholar
• Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. Nat Rev Cancer 2013; 13:739-52; PMID:24060865; http://dx.doi.org/10.1038/nrc3581
   PubMed Web of Science ®Google Scholar
• Yu GT, Bu LL, Huang CF, Zhang WF, Chen WJ, Gutkind JS, Kulkarni AB, Sun ZJ. PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPalpha axis in HPV negative head and neck squamous cell carcinoma. Oncotarget 2015; 6:42067-80; PMID:26573233; http://dx.doi.org/10.18632/oncotarget.5955.
   PubMed Web of Science ®Google Scholar
• Buchbinder E, Hodi FS. Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest 2015; 125:3377-83; PMID:26325034; http://dx.doi.org/10.1172/JCI80012
   PubMed Web of Science ®Google Scholar
• Chevolet I, Speeckaert R, Schreuer M, Neyns B, Krysko O, Bachert C, Hennart B, Allorge D, van Geel N, Van Gele M et al. Characterization of the immune network of IDO, tryptophan metabolism, PD-L1, and in circulating immune cells in melanoma. Oncoimmunology 2015; 4:e982382; PMID:25949897; http://dx.doi.org/10.4161/2162402X.2014.982382
   PubMedGoogle Scholar
• Kaufmann DE, Walker BD. PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention. J Immunol 2009; 182:5891-7; PMID:19414738; http://dx.doi.org/10.4049/jimmunol.0803771
   PubMed Web of Science ®Google Scholar
• Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002; 3:611-8; PMID:12087419; http://dx.doi.org/10.1038/ni0702-611
   PubMed Web of Science ®Google Scholar
• Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271:1734-6; PMID:8596936; http://dx.doi.org/10.1126/science.271.5256.1734
   PubMed Web of Science ®Google Scholar
• Jie HB, Schuler PJ, Lee SC, Srivastava RM, Argiris A, Ferrone S, Whiteside TL, Ferris RL. CTLA-4(+) Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis. Cancer Res 2015; 75:2200-10; PMID:25832655; http://dx.doi.org/10.1158/0008-5472.CAN-14-2788
   PubMed Web of Science ®Google Scholar
• Ewing MM, Karper JC, Abdul S, de Jong RC, Peters HA, de Vries MR, Redeker A, Kuiper J, Toes RE, Arens R et al. T-cell co-stimulation by CD28-CD80/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development. Int J Cardiol 2013; 168:1965-74; PMID:23351788; http://dx.doi.org/10.1016/j.ijcard.2012.12.085
   PubMed Web of Science ®Google Scholar
• Lee CH, Chang JS, Syu SH, Wong TS, Chan JY, Tang YC, Yang ZP, Yang WC, Chen CT, Lu SC et al. IL-1beta promotes malignant transformation and tumor aggressiveness in oral cancer. J Cell Physiol 2015; 230:875-84; PMID:25204733; http://dx.doi.org/10.1002/jcp.24816
   PubMed Web of Science ®Google Scholar
• Oppenheim JJ, Zachariae CO, Mukaida N, Matsushima K. Properties of the novel proinflammatory supergene “intercrine” cytokine family. Annu Rev Immunol 1991; 9:617-48; PMID:1910690; http://dx.doi.org/10.1146/annurev.iy.09.040191.003153
   PubMed Web of Science ®Google Scholar
• Remus EW, Sayeed I, Won S, Lyle AN, Stein DG. Progesterone protects endothelial cells after cerebrovascular occlusion by decreasing MCP-1- and CXCL1-mediated macrophage infiltration. Exp Neurol 2015; 271:401-8; PMID:26188381; http://dx.doi.org/10.1016/j.expneurol.2015.07.010
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
   PubMed Web of Science ®Google Scholar
• Swanson MS, Sinha UK. Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer-review of current data. Oral Oncol 2015; 51:12-5; PMID:25459157; http://dx.doi.org/10.1016/j.oraloncology.2014.10.010
   PubMed Web of Science ®Google Scholar
• Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 2013; 210:1695-710; PMID:23897981; http://dx.doi.org/10.1084/jem.20130579
   PubMed Web of Science ®Google Scholar
• Yu GT, Bu LL, Zhao YY, Liu B, Zhang WF, Zhao YF, Zhang L, Sun ZJ. Inhibition of mTOR reduce Stat3 and PAI related angiogenesis in salivary gland adenoid cystic carcinoma. Am J Cancer Res 2014; 4:764-75; PMID:25520866
   PubMed Web of Science ®Google Scholar
• Sun ZJ, Zhang L, Hall B, Bian Y, Gutkind JS, Kulkarni AB. Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model. Clin Cancer Res 2012; 18:5304-13; PMID:22859719; http://dx.doi.org/10.1158/1078-0432.CCR-12-1371
   PubMed Web of Science ®Google Scholar